Background The molecular profiling of patients with advanced non-small-cell lung cancer
(NSCLC) for known oncogenic drivers is recommended during routine care. Nationally …

8000 Background: Personalized medicine is now a reality for advanced NSCLC pts on the
basis of routine screening for EGFR mutation and ALK gene fusion assessment. The French …

Background: Genomic testing to identify driver mutations that enable targeted therapy is
emerging for patients with non–small-cell lung cancer (NSCLC). We report the …

Background Testing for EGFR mutations and ALK rearrangement has become standard in
managing advanced nonsmall-cell lung cancer (NSCLC). However, many institutions in …

Purpose We conducted a basket clinical trial to assess the feasibility of such a design
strategy and to independently evaluate the effects of multiple targeted agents against …

Background Findings from the phase 3 FLEX study showed that the addition of cetuximab to
cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and …

Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …

Objectives An increasing number of treatment-determining biomarkers has been identified in
non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable …

Lung cancer diagnostics have progressed greatly in the previous decade. Development of
molecular testing to identify an increasing number of potentially clinically actionable genetic …

Abstract In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society
of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in …